Review article: Drug therapy for non-alcoholic fatty liver disease

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 2, 2006, Pages 207-215

  Comar, K M ^a   Sterling, R K ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTIOXIDANT; ASCORBIC ACID; BETAINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; INSULIN SENSITIZING AGENT; LIVER PROTECTIVE AGENT; LOSARTAN; METFORMIN; PENTOXIFYLLINE; PIOGLITAZONE; PROBUCOL; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; TAMOXIFEN; TROGLITAZONE; URSODEOXYCHOLIC ACID;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ACUTE HEPATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ALCOHOLIC FATTY LIVER; CHOLESTASIS; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DISEASE EXACERBATION; ECHOGRAPHY; FATTY LIVER; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEALTH HAZARD; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; IATROGENIC DISEASE; IDIOPATHIC DISEASE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER TOXICITY; METABOLIC SYNDROME X; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; UNPLEASANT DREAM; WEIGHT GAIN; WEIGHT REDUCTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIOXIDANTS; ASCORBIC ACID; BETAINE; CHOLAGOGUES AND CHOLERETICS; ENZYME INHIBITORS; FATTY LIVER; HUMANS; HYPOGLYCEMIC AGENTS; LIPOTROPIC AGENTS; METFORMIN; PENTOXIFYLLINE; PROBUCOL; THIAZOLIDINEDIONES; URSODEOXYCHOLIC ACID; VITAMIN E;

EID: 33644900462     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02751.x     Document Type: Review

References (66)

1. Matteoni CA Younossi ZM Gramlich T Boparai N Liu YC McCullough AJ Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity Gastroenterology 1999 116 1413 9
2. Powell EE Cooksley WG Hanson R Searle J Halliday JW Powell LW The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years Hepatology 1990 11 74 80
3. Teli MR James OF Burt AD Bennett MK Day CP The natural history of nonalcoholic fatty liver: a follow-up study Hepatology 1995 22 1714 9
4. Wanless IR Lentz JS Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors Hepatology 1990 12 1106 10
5. Contos MJ Sanyal AJ The clinicopathologic spectrum and management of nonalcoholic fatty liver disease Adv Anat Pathol 2002 9 37 51
6. Brunt EM Nonalcoholic steatohepatitis Semin Liver Dis 2004 24 3 20
7. Falck-Ytter Y Younossi ZM Marchesini G McCullough AJ Clinical features and natural history of nonalcoholic steatosis syndromes Semin Liver Dis 2001 21 17 26
8. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 2002 106 3143 421
9. Sanyal AJ AGA technical review on nonalcoholic fatty liver disease Gastroenterology 2002 123 1705 25
10. Bacon BR Farahvash MJ Janney CG Neuschwander-Tetri BA Nonalcoholic steatohepatitis: an expanded clinical entity Gastroenterology 1994 107 1103 9
11. Ludwig J Viggiano TR McGill DB Oh BJ Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease Mayo Clin Proc 1980 55 434 8
12. Sanyal AJ Campbell-Sargent C Mirshahi F et al Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities Gastroenterology 2001 120 1183 92
13. Chitturi S Farrell GC Etiopathogenesis of nonalcoholic steatohepatitis Semin Liver Dis 2001 21 27 41
14. Diehl AM Fatty liver, hypertension, and the metabolic syndrome Gut 2004 53 923 4
15. Marchesini G Bugianesi E Forlani G et al Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome Hepatology 2003 37 917 23
16. Reid BM Sanyal AJ Evaluation and management of non-alcoholic steatohepatitis Eur J Gastroenterol Hepatol 2004 16 1117 22
17. Ratziu V Charlotte F Heurtier A et al Sampling variability of liver biopsy in nonalcoholic fatty liver disease Gastroenterology 2005 128 1898 906
18. Fusamoto H Suzuki K Hayashi N et al Obesity and liver disease: evaluation of fatty infiltration of the liver using ultrasonic attenuation J Nutr Sci Vitaminol (Tokyo) 1991 37 Suppl. S71 7
19. Yajima Y Ohta K Narui T Abe R Suzuki H Ohtsuki M Ultrasonographical diagnosis of fatty liver: significance of the liver-kidney contrast Tohoku J Exp Med 1983 139 43 50
20. Saadeh S Younossi ZM Remer EM et al The utility of radiological imaging in nonalcoholic fatty liver disease Gastroenterology 2002 123 745 50
21. Joseph AE Saverymuttu SH al-Sam S Cook MG Maxwell JD Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease Clin Radiol 1991 43 26 31
22. Fagan TJ Letter: nomogram for Bayes theorem N Engl J Med 1975 293 257
23. Joy D Thava VR Scott BB Diagnosis of fatty liver disease: is biopsy necessary Eur J Gastroenterol Hepatol 2003 15 539 43
24. Adams LA Lymp JF St Sauver J et al The natural history of nonalcoholic fatty liver disease: a population-based cohort study Gastroenterology 2005 129 113 21
25. Hickman IJ Jonsson JR Prins JB et al Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life Gut 2004 53 413 9
26. Dixon JB Bhathal PS Hughes NR O'Brien PE Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss Hepatology 2004 39 1647 54
27. Weltman MD Farrell GC Liddle C Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation Gastroenterology 1996 111 1645 53
28. Seki S Kitada T Yamada T Sakaguchi H Nakatani K Wakasa K In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases J Hepatol 2002 37 56 62
29. Lavine JE Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study J Pediatr 2000 136 734 8
30. Hasegawa T Yoneda M Nakamura K Makino I Terano A Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study Aliment Pharmacol Ther 2001 15 1667 72
31. Harrison SA Torgerson S Hayashi P Ward J Schenker S Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis Am J Gastroenterol 2003 98 2485 90
32. Sanyal AJ Mofrad PS Contos MJ et al A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis Clin Gastroenterol Hepatol 2004 2 1107 15
33. Miller III ER. Pastor-Barriuso R Dalal D Riemersma RA Appel LJ Guallar E Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality Ann Intern Med 2005 142 37 46
34. Abdelmalek MF Angulo P Jorgensen RA Sylvestre PB Lindor KD Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study Am J Gastroenterol 2001 96 2711 7
35. Marceau P Biron S Hould FS et al Liver pathology and the metabolic syndrome X in severe obesity J Clin Endocrinol Metab 1999 84 1513 7
36. Marchesini G Brizi M Morselli-Labate AM et al Association of nonalcoholic fatty liver disease with insulin resistance Am J Med 1999 107 450 5
37. Cusi K Consoli A DeFronzo RA Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus J Clin Endocrinol Metab 1996 81 4059 67
38. DeFronzo RA Barzilai N Simonson DC Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects J Clin Endocrinol Metab 1991 73 1294 301
39. Stumvoll M Nurjhan N Perriello G Dailey G Gerich JE Metabolic effects of metformin in non-insulin-dependent diabetes mellitus N Engl J Med 1995 333 550 4
40. Argaud D Roth H Wiernsperger N Leverve XM Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes Eur J Biochem 1993 213 1341 8
41. Lenhard JM Kliewer SA Paulik MA Plunket KD Lehmann JM Weiel JE Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways Biochem Pharmacol 1997 54 801 8
42. Zhou G Myers R Li Y et al Role of AMP-activated protein kinase in mechanism of metformin action J Clin Invest 2001 108 1167 74
43. Lin HZ Yang SQ Chuckaree C Kuhajda F Ronnet G Diehl AM Metformin reverses fatty liver disease in obese, leptin-deficient mice Nat Med 2000 6 998 1003
44. Marchesini G Brizi M Bianchi G Tomassetti S Zoli M Melchionda N Metformin in non-alcoholic steatohepatitis Lancet 2001 358 893 4
45. Nair S Diehl AM Wiseman M Farr Jr GH. Perrillo RP Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial Aliment Pharmacol Ther 2004 20 23 8
46. Uygun A Kadayifci A Isik AT et al Metformin in the treatment of patients with non-alcoholic steatohepatitis Aliment Pharmacol Ther 2004 19 537 44
47. Yoshiji H Kuriyama S Yoshii J et al Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats Hepatology 2001 34 745 50
48. Heller FR Martinet JP Henrion J Schapira M Gallez JF The rationale for using ursodeoxycholic acid in chronic liver disease Acta Gastroenterol Belg 1990 53 402 8
49. Scholmerich J Becher MS Schmidt K et al Influence of hydroxylation and conjugation of bile salts on their membrane-damaging properties - studies on isolated hepatocytes and lipid membrane vesicles Hepatology 1984 4 661 6
50. Laurin J Lindor KD Crippin JS et al Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study Hepatology 1996 23 1464 7
51. Lindor KD Kowdley KV Heathcote EJ et al Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial Hepatology 2004 39 770 8
52. Tilg H Diehl AM Cytokines in alcoholic and nonalcoholic steatohepatitis N Engl J Med 2000 343 1467 76
53. Warne JP Tumour necrosis factor alpha: a key regulator of adipose tissue mass J Endocrinol 2003 177 351 5
54. Wigg AJ Roberts-Thomson IC Dymock RB McCarthy PJ Grose RH Cummins AG The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis Gut 2001 48 206 11
55. Neuner P Klosner G Schauer E et al Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells Immunology 1994 83 262 7
56. Adams LA Zein CO Angulo P Lindor KD A pilot trial of pentoxifylline in nonalcoholic steatohepatitis Am J Gastroenterol 2004 99 2365 8
57. Mayerson AB Hundal RS Dufour S et al The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes Diabetes 2002 51 797 802
58. Galli A Crabb DW Ceni E et al Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro Gastroenterology 2002 122 1924 40
59. Caldwell SH Hespenheide EE Redick JA Iezzoni JC Battle EH Sheppard BL A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis Am J Gastroenterol 2001 96 519 25
60. Gitlin N Julie NL Spurr CL Lim KN Juarbe HM Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone Ann Intern Med 1998 129 36 8
61. Watkins PB Whitcomb RW Hepatic dysfunction associated with troglitazone N Engl J Med 1998 338 916 7
62. Neuschwander-Tetri BA Brunt EM Wehmeier KR Oliver D Bacon BR Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone Hepatology 2003 38 1008 17
63. Chalasani N Teal E Hall SD Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes Am J Gastroenterol 2005 100 1317 21
64. Promrat K Lutchman G Uwaifo GI et al A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis Hepatology 2004 39 188 96
65. Araki T Kitaoka H Antioxidative properties of probucol estimated by the reactivity with superoxide and by electrochemical oxidation Chem Pharm Bull (Tokyo) 2001 49 943 7
66. Merat S Malekzadeh R Sohrabi MR et al Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study J Hepatol 2003 38 414 8